Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase (NECT-FIELD)

This study has been completed.
Sponsor:
Collaborators:
Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), DRC
Swiss Tropical & Public Health Institute
Information provided by (Responsible Party):
Drugs for Neglected Diseases
ClinicalTrials.gov Identifier:
NCT00906880
First received: May 19, 2009
Last updated: May 30, 2013
Last verified: May 2013